Evaluation of the Effect of Thiabendazole on the Growth and Proliferation of Oral Squamous Cell Carcinoma Organoids

Necessity of Project Implementation

Oral squamous cell carcinoma (OSCC) is one of the most common types of oral cancer, associated with a high mortality rate. Existing treatments, such as cisplatin, despite their effectiveness, often cause significant side effects, highlighting the need for novel therapies with fewer adverse effects. Thiabendazole, a drug with potential anti-cancer properties, could be a promising candidate for treating this type of cancer. Investigating the effects of this drug on morphology, proliferation, and apoptosis in organoid models may provide valuable insights for improving future treatments and reducing side effects. Despite therapeutic advancements, challenges such as chemoresistance and drug-induced toxicity emphasize the urgent need for new and efficient treatment strategies. In this context, organoid models, advanced three-dimensional systems closely resembling actual tumors, serve as powerful tools for studying disease mechanisms and evaluating drug efficacy. Studies suggest that thiabendazole can inhibit signaling pathways involved in angiogenesis and cell proliferation, thereby reducing cancer cell growth. However, there is limited information about the impact of thiabendazole on oral squamous cell carcinoma organoids. Exploring its effects on the growth and proliferation of these organoids could identify potential mechanisms of action and pave the way for novel combination therapies.

Principal Investigator: Dr. Amir Jalal Abbasi
Start Year: 2024